210 mg brodalumab + 140 mg brodalumab + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis
Conditions
Psoriatic Arthritis
Trial Timeline
Mar 1, 2014 → Oct 1, 2015
NCT ID
NCT02024646About 210 mg brodalumab + 140 mg brodalumab + Placebo
210 mg brodalumab + 140 mg brodalumab + Placebo is a phase 3 stage product being developed by Bausch Health for Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02024646. Target conditions include Psoriatic Arthritis.
What happened to similar drugs?
5 of 20 similar drugs in Psoriatic Arthritis were approved
Approved (5) Terminated (0) Active (15)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02024646 | Phase 3 | Completed |
| NCT02029495 | Phase 3 | Terminated |
| NCT01708590 | Phase 3 | Terminated |
Competing Products
20 competing products in Psoriatic Arthritis